Spago Nanomedical AB (publ) (SPAGO.ST)

SEK 0.19

(7.39%)

Market Cap (In SEK)

65.8 Million

Revenue (In SEK)

1.2 Million

Net Income (In SEK)

-42.22 Million

Avg. Volume

172.5 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.151-0.428
PE
-
EPS
-
Beta Value
2.006
ISIN
SE0004899474
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Mats Hansen M.Sc., Ph.D.
Employee Count
-
Website
https://spagonanomedical.se
Ipo Date
2013-01-16
Details
Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.